“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

17 June 2019
Pharma

Visiongain has launched a new pharma report Global Ophthalmic Drugs Market Forecast 2019-2029: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs.

The market for ophthalmic drugs is relatively fragmented with a large number of drugs competing for market shares. We note that there are many drugs within the various sectors of the market that have lost exclusivity in the major markets and have therefore been subjected to generic drug competition. Despite generic penetration, the global market for ophthalmic drugs is a growing one with a hive of activities and multiple products in various stages of development.

The lead analyst of the report commented "The market for ophthalmic drugs is a growing one. Although it is currently dominated by a handful of companies, the market still provides opportunities for companies looking to introduce innovative solutions to meet the chronic needs within the market.

Blockbuster drugs are becoming increasingly few within the market as drugs become more targeted. We note that future growth within ophthalmic drugs will likely be driven by innovation from smaller players, possibly in partnership with one of the major companies in the market. The increased demand for drugs and the efforts going into R&D will benefit these smaller players and help to stimulate their growth over the forecast period. With many targeting eye diseases and conditions where significant unmet treatment needs exist, rapid uptake of these products can be expected."

Leading companies featured in the report include Allergan (Actavis), Bayer, Novartis, Pfizer, Regeneron, Roche, Santen, Senju, Valeant and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever